Pathophysiology of bone metastases;Pathophysiologie des métastases osseuses

Progres en Urologie

Volumn 13, Issue 2 SUPPL. 1, 2003, Pages 9-17

  Chappard, Daniel ^a   Legrand, Erick ^a,b   Massin, Philippe ^a,b   Basle, Michel Félix ^a   Audran, Maurice ^a,b  

^a Universite d'Angers   (France)

^b ANGERS UNIVERSITY HOSPITAL   (France)

Author keywords

Bone metastases; Cytokines; Osteolysis; Osteosclerosis; Pathophysiology

Indexed keywords

CYTOKINE; BISPHOSPHONIC ACID DERIVATIVE;

BONE LESION; BONE METASTASIS; BONE TUMOR; CANCER CELL; CELL MIGRATION; HEMATOLOGIC MALIGNANCY; HEMATOLOGY; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HUMAN; LYMPHOMA; MYELOMA; OSTEOLYSIS; OSTEOSCLEROSIS; PATHOPHYSIOLOGY; REVIEW; TUMOR CELL; BONE REMODELING; LYMPH NODE METASTASIS; METASTASIS; PATHOLOGY; PHYSIOLOGY;

BONE NEOPLASMS; BONE REMODELING; DIPHOSPHONATES; HUMANS; LYMPHATIC METASTASIS; OSTEOLYSIS; OSTEOSCLEROSIS;

EID: 0041765820     PISSN: 11667087     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. BAO, L., LODA, M., JANMEY, P.A., STEWART, R., ANAND-APTE, B., ZETTER, B.R. Thymosin beta 15: a novel regulator of tumor cell motility upregulated in metastatic prostate cancer. Nat. Med., 1996, 2, 1322-1328.
2. BATAILLE, R., MANOLAGAS, S.C., BERENSON, J.R. Pathogenesis and management of bone lesions in multiple myeloma. Hematol./Oncol. Clin. North Amer., 1997, 11, 349-361.
3. BERRUTI, A., DOGLIOTTI, L., TUCCI, M., R., T., FONTANA, D., ANGELI, A. Metabolic bone disease induced by prostate cancer: rationale for the use of bisphosphonates. J. Urol., 2002, 166, 2023-2031.
4. BOUIZAR, Z., SPYRATOS, F., DEYTIEUX, S., DE VERNEJOUL, M.C., JULLIENNE, A. Polymerase chain reaction analysis of parathyroid hormone-related protein gene expression in breast cancer patients and occurrence of bone metastases. Cancer Res., 1993, 53, 5076-5078.
5. DEFTOS, L.J. Prostate carcinoma: production of bioactive factors. Cancer., 2000, 88, 3002-3008.
6. ERLEBACHER, A., FILVAROFF, E.H., YE, J.Q., DERYNCK, R. Osteoblastic responses to TGF-beta during bone remodeling. Mol. Biol. Cell., 1998, 9, 1903-1918.
7. FIELDER, P.J., ROSENFELD, R.G., GRAVES, H.C., GRANDBOIS, K., MAACK, C.A., SAWAMURA, S., OGAWA, Y., SOMMER, A., COHEN, P. Biochemical analysis of prostate specific antigen-proteolyzed insulin-like growth factor binding protein-3. Growth Regul., 1994, 4.
8. FLEISCH, H. Bisphosphonates in bone disease. From the laboratory to the patient. 2000. San Diego: Academic Press.
9. FROST, H.M. Some effects of basic multicellular unit-based remodelling on photon absorptiometry of trabecular bone. Bone Miner., 1989, 7, 47-65.
10. GREEN, J.R., CLEZARDIN, P. Mechanisms of bisphosphonate effects on osteoclasts, tumor cell growth, and metastasis. Am J Clin Oncol., 2002, 25S1, 3-9.
11. GUISE, T.A., MUNDY, G.R. Cancer and bone. Endocr. Rev., 1998, 19, 18-54.
12. HORTOBAGY, I.G.N. Novel approaches to the management of bone metastases in patients with breast cancer. Semin Oncol., 2002, 29, 134-144.
13. JILKA, R.L. Cytokines, bone remodeling, and estrogen deficiency. Bone., 1998, 23, 75-81.
14. KAMBY, C., RASMUSSEN, B.B., KRISTENSEN, B. Oestrogen receptor status of primary breast carcinomas and their metastases. Relation to pattern of spread and survival after recurrence. Brit. J. Cancer., 1989, 60, 252-257.
15. KOSTENUIK, P.J., SANCHEZ-SWEATMAN, O., ORR, F.W., SINGH, G. Bone cell matrix promotes the adhesion of human prostatic carcinoma cells via the alpha 2 beta 1 integrin. Clin. Exp. Metastasis., 1996, 14, 19-26.
16. KOUTSILIERIS, M. Skeletal metastases in advanced prostate cancer: cell biology and therapy. Crit. Rev. Oncol./Hematol., 1995, 18, 51-64.
17. LACEY, D.L., TIMMS, E., TAN, H.L., KELLEY, M.J., DUNSTAN, C.R., BURGESS, T., ELLIOTT, R., COLOMBERO, A., ELLIOTT, G., SCULLY, S., HSU, H., SULLIVAN, J., HAWKINS, N., DAVY, E., CAPPARELLI, C., ELI, A., QIAN, Y.X., KAUFMAN, S., SAROSI, I., SHALHOUB, V., SENALDI, G., GUO, J., DELANEY, J., BOYLE, W.J. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell., 1998, 93, 165-176.
18. LEE Y, SCHWARZ E, DAVIES M, JO M, GATES J, WU J, ZHANG X, JR., L. Differences in the cytokine profiles associated with prostate cancer cell induced osteoblastic and osteolytic lesions in bone. J. Orthop. Res., 2003, 21, 62-72.
19. MATSUURA, N., PUZON-MCLAUGHLIN, W., IRIE, A., MORIKAWA, Y., KAKUDO, K., TAKADA, Y. Induction of experimental bone metastasis in mice by transfection of integrin alpha 4 beta 1 into tumor cells. Am J Pathol., 1996, 148, 55-61.
20. MUNDY, G.R., DEMARTINO, S., ROWE, D.W. Collagen and collagen-derived fragments are chemotactic for tumor cells. J. Clin. Invest., 1981, 68, 1102-1105.
21. OURSLER, M.J. Osteoclast synthesis and secretion and activation of latent transforming growth factor beta. J. Bone Miner. Res., 1994, 9, 443-452.
22. POWELL, G.J., SOUTHBY, J., DANKS, J.A., STILLWELL, R.G., HAYMAN, J.A., HENDERSON, M.A., BENNETT, R.C., MARTIN, T.J. Localization of parathyroid hormone-related protein in breast cancer metastases: increased incidence in bone compared with other sites. Cancer Res., 1991, 51, 3059-3061.
23. PUGSLEY, M.K., TABRIZCHI, R. The vascular system: An overview of structure and function. J. Pharmacol. Toxicol. Meth., 2000, 44, 333-340.
24. ROODMAN, G.D. Cell biology of the osteoclast. Exp. Hematol., 1999, 27, 1229-1241.
25. SUGIHARA, A., MAEDA, O., TSUJI, M., TSUJIMURA, T., NAKATA, Y., AKEDO, H., KOTAKE, T., TERADA, N. Expression of cytokines enhancing the osteoclast activity, and parathyroid hormone-related protein in prostatic cancers before and after endocrine therapy: an immunohistochemical study. Oncology Reports., 1998, 5, 1389-1394.
26. TEITELBAUM, S. Bone resorption by osteoclast. Science., 2000, 289, 1504-1508.
27. THOMAS, R.J., GUISE, T.A., YIN, J.J., ELLIOTT, J., HORWOOD, N.J., MARTIN, T.J., GILLESPIE, M.T. Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology., 1999, 140, 4451-4458.
28. UDAGAWA, N. Mechanisms involved in bone resorption. Biogerontol., 2002, 3, 79-83.
29. VARGAS, S.J., GILLESPIE, M.T., POWELL, G.J., SOUTHBY, J., DANKS, J.A., MOSELEY, J.M., MARTIN, T.J. Localization of parathyroid hormone-related protein mRNA expression in breast cancer and metastatic lesions by in situ hybridization. J. Bone Miner. Res., 1992, 7, 971-979.
30. YASUDA, H., SHIMA, N., NAKAGAWA, N., YAMAGUCHI, K., KINOSAKI, M., MOCHIZUKI, S., TOMOYASU, A., YANO, K., GOTO, M., MURAKAMI, A., TSUDA, E., MORINAGA, T., HIGASHIO, K., UDAGAWA, N., TAKAHASHI, N., SUDA, T. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis- inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl. Acad. Sci. U. S. A., 1998, 95, 3597-3602.